Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study
Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses final overall survival (OS) analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm — a different of 15.7 months. This is truly a remarkable improvement, Swain says.
Monoclonal antibodies have changed the trajectory of the disease in many patients with HER2-positive metastatic breast cancer, Swain says, and they are now able to live fairly normal lives.
<<<
